Wesolowski John M 4
4 · INTENSITY THERAPEUTICS, INC. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Intensity Therapeutics (INTS) Principal Accounting Officer Buys 3,688 Shares
What Happened
John M. Wesolowski, Principal Accounting Officer of Intensity Therapeutics (INTS), acquired 3,688 shares of the company's common stock on June 30, 2026. The shares were purchased under the company's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) at $3.48 per share, for a total of approximately $12,853. The filing notes this transaction is reported voluntarily and is exempt under Rule 16b-3.
Key Details
- Transaction date: 2026-06-30 (filed 2026-07-01).
- Transaction type: Acquisition under ESPP (reported as "Grant, award or other acquisition (A)").
- Price and value: $3.48 per share; total ~ $12,853.
- Footnotes: purchase was exempt under Rule 16b-3(c) and 16b-3(d) (F1); price reflects an 85% discount to the closing price on 6/30/2026 per the ESPP (F2).
- Reverse split: All reported amounts adjusted for the issuer's 1-for-25 reverse split effective 2/18/2026 (F3).
- Shares owned after transaction: not specified in the filing.
- Timeliness: Filing appears timely (reported the next day).
Context
An ESPP purchase is a routine employee benefit that lets employees buy stock at a discounted price (here, 85% of the closing price). While insider purchases can be interpreted as a modest positive signal, this transaction is relatively small in dollar terms (~$12.9k) and reflects participation in the company plan rather than a large directional bet.
Insider Transaction Report
- Award
Common Stock, $0.0001 Par Value
[F1][F2][F3]2026-06-30$3.48/sh+3,688$12,853→ 7,102 total
Footnotes (3)
- [F1]The Reporting Person is voluntarily reporting the acquisition of shares under the Issuer's Amended and Restated 2024 Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c) and Rule 16b-3(d).
- [F2]In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2026.
- [F3]On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split.